Rushang D. Patel, MD, discusses the background to the single center experience with ruxolitinib as treatment of patients with chronic graft-versus-host disease.
Rushang D. Patel, MD
Advertisement
Articles by Rushang D. Patel, MD
Advertisement
Latest Updated Articles
Ruxolitinib Appears Promising as Treatment of Chronic Graft-Versus-Host DiseasePublished: February 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
